Supplemental Guarantor/Non-Guarantor Financial Information Consolidating Statement of Cash Flows (Details) (USD $) | 9 Months Ended |
In Thousands, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Cash flows from operating activities | $805,933 | $802,163 |
Additions to properties, plants and equipment | -307,476 | -255,090 |
Payments to Acquire Businesses, Net of Cash Acquired | 0 | 11,301 |
Proceeds from sale of assets | 14,711 | 5,802 |
Investment in Sabine Biofuels | -5,000 | -3,000 |
Net repayment from (advances to) Sabine Biofuels | 10,021 | -11,040 |
Net repayment from (advances to) Sabine Biofuels | ' | 11,040 |
Purchases of marketable securities | -762,224 | -672,701 |
Sales and maturities of marketable securities | 863,769 | 646,301 |
Net Advances to Parent | 0 | 0 |
Net cash used for investing activities | -247,856 | -332,128 |
Net repayments under credit agreement b HEP | ' | 56,000 |
Net borrowings under credit agreement b HEP | -192,000 | ' |
Redemption of Senior Notes - HEP | 0 | -300,973 |
Proceeds from common unit offerings | 0 | 146,888 |
Principal tender on senior notes - HEP | -156,188 | ' |
Purchase of treasury stock | -133,150 | -184,947 |
Contribution from General Partner | ' | 0 |
Dividends | -485,766 | -485,411 |
Excess tax benefit from equity based compensation | 4,482 | 2,739 |
Deferred financing costs and other | -3,995 | 668 |
Net advances from subsidiaries | 0 | 0 |
Net cash provided by (used for) financing activities | -642,154 | -933,250 |
Increase (decrease) for the period | -84,077 | -463,215 |
Beginning of period | 940,103 | 1,757,699 |
End of period | 856,026 | 1,294,484 |
Parent Company [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Cash flows from operating activities | -260,533 | -377,762 |
Additions to properties, plants and equipment | -8,373 | -8,056 |
Proceeds from sale of assets | ' | 0 |
Investment in Sabine Biofuels | 0 | 0 |
Net repayment from (advances to) Sabine Biofuels | 0 | ' |
Net repayment from (advances to) Sabine Biofuels | ' | 0 |
Purchases of marketable securities | -762,224 | -672,701 |
Sales and maturities of marketable securities | 863,769 | 646,301 |
Net Advances to Parent | 0 | 0 |
Net cash used for investing activities | 93,172 | -34,456 |
Net borrowings under credit agreement b HEP | 0 | ' |
Redemption of Senior Notes - HEP | ' | -300,973 |
Principal tender on senior notes - HEP | 0 | ' |
Purchase of treasury stock | -133,150 | -184,947 |
Contribution from General Partner | ' | 0 |
Dividends | -485,766 | -485,411 |
Distributions to noncontrolling interest | 0 | 0 |
Excess tax benefit from equity based compensation | 4,482 | 2,739 |
Purchase of units for restricted grants - HEP | 0 | ' |
Deferred financing costs and other | 3,257 | 0 |
Net advances from subsidiaries | 703,859 | 841,821 |
Net cash provided by (used for) financing activities | 86,168 | -53,327 |
Increase (decrease) for the period | -81,193 | -465,545 |
Beginning of period | 931,920 | 1,748,808 |
End of period | 850,727 | 1,283,263 |
Guarantor Restricted Subsidiaries [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Cash flows from operating activities | 930,722 | 1,066,429 |
Additions to properties, plants and equipment | -298,272 | -247,034 |
Proceeds from sale of assets | ' | -3,321 |
Investment in Sabine Biofuels | -5,000 | -3,000 |
Net repayment from (advances to) Sabine Biofuels | 10,021 | ' |
Net repayment from (advances to) Sabine Biofuels | ' | 11,040 |
Purchases of marketable securities | 0 | 0 |
Sales and maturities of marketable securities | 0 | 0 |
Net Advances to Parent | -649,294 | -801,939 |
Net cash used for investing activities | -927,834 | -1,070,993 |
Net borrowings under credit agreement b HEP | 0 | ' |
Redemption of Senior Notes - HEP | ' | 0 |
Proceeds from common unit offerings | ' | 0 |
Principal tender on senior notes - HEP | 0 | ' |
Purchase of treasury stock | 0 | 0 |
Contribution from General Partner | ' | 0 |
Dividends | 0 | 0 |
Distributions to noncontrolling interest | 0 | 0 |
Excess tax benefit from equity based compensation | 0 | 0 |
Purchase of units for restricted grants - HEP | 0 | ' |
Deferred financing costs and other | 1,231 | 912 |
Net advances from subsidiaries | 0 | 0 |
Net cash provided by (used for) financing activities | -1,231 | 912 |
Increase (decrease) for the period | 1,657 | -3,652 |
Beginning of period | 1,817 | 3,652 |
End of period | 3,474 | 0 |
Non Guarantor Restricted Subsidiaries [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Cash flows from operating activities | 55,047 | 41,380 |
Additions to properties, plants and equipment | -831 | 0 |
Proceeds from sale of assets | ' | 0 |
Investment in Sabine Biofuels | 0 | 0 |
Net repayment from (advances to) Sabine Biofuels | 0 | ' |
Net repayment from (advances to) Sabine Biofuels | ' | 0 |
Purchases of marketable securities | 0 | 0 |
Sales and maturities of marketable securities | 0 | 0 |
Net Advances to Parent | -54,565 | -39,882 |
Net cash used for investing activities | -55,396 | -39,882 |
Net borrowings under credit agreement b HEP | 0 | ' |
Redemption of Senior Notes - HEP | ' | 0 |
Proceeds from common unit offerings | ' | 0 |
Principal tender on senior notes - HEP | 0 | ' |
Purchase of treasury stock | 0 | 0 |
Contribution from General Partner | ' | 1,499 |
Dividends | 0 | 0 |
Distributions to noncontrolling interest | 0 | 0 |
Excess tax benefit from equity based compensation | 0 | 0 |
Purchase of units for restricted grants - HEP | 0 | ' |
Deferred financing costs and other | -493 | 0 |
Net advances from subsidiaries | 0 | 0 |
Net cash provided by (used for) financing activities | 493 | -1,499 |
Increase (decrease) for the period | 144 | -1 |
Beginning of period | 14 | 2 |
End of period | 158 | 1 |
Eliminations [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Cash flows from operating activities | 0 | 0 |
Additions to properties, plants and equipment | 0 | 0 |
Payments to Acquire Businesses, Net of Cash Acquired | ' | 0 |
Proceeds from sale of assets | 0 | 0 |
Investment in Sabine Biofuels | 0 | 0 |
Net repayment from (advances to) Sabine Biofuels | 0 | ' |
Net repayment from (advances to) Sabine Biofuels | ' | 0 |
Purchases of marketable securities | 0 | 0 |
Sales and maturities of marketable securities | 0 | 0 |
Net Advances to Parent | 703,859 | 841,821 |
Net cash used for investing activities | 703,859 | 841,821 |
Net repayments under credit agreement b HEP | ' | 0 |
Net borrowings under credit agreement b HEP | 0 | ' |
Redemption of Senior Notes - HEP | ' | 0 |
Proceeds from common unit offerings | ' | 0 |
Principal tender on senior notes - HEP | 0 | ' |
Purchase of treasury stock | 0 | 0 |
Contribution from General Partner | ' | 0 |
Dividends | 0 | 0 |
Distributions to noncontrolling interest | 0 | 0 |
Excess tax benefit from equity based compensation | 0 | 0 |
Purchase of units for restricted grants - HEP | 0 | 0 |
Deferred financing costs and other | 0 | 0 |
Net advances from subsidiaries | 703,859 | 841,821 |
Net cash provided by (used for) financing activities | -703,859 | -841,821 |
Increase (decrease) for the period | 0 | 0 |
Beginning of period | 0 | 0 |
End of period | 0 | 0 |
Holly Frontier Corp. Before Consolidation Of HEP [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Cash flows from operating activities | 725,236 | 730,047 |
Additions to properties, plants and equipment | -307,476 | -255,090 |
Proceeds from sale of assets | ' | -3,321 |
Investment in Sabine Biofuels | -5,000 | -3,000 |
Net repayment from (advances to) Sabine Biofuels | 10,021 | ' |
Net repayment from (advances to) Sabine Biofuels | ' | 11,040 |
Purchases of marketable securities | -762,224 | -672,701 |
Sales and maturities of marketable securities | 863,769 | 646,301 |
Net Advances to Parent | 0 | 0 |
Net cash used for investing activities | -186,199 | -303,510 |
Net borrowings under credit agreement b HEP | 0 | ' |
Redemption of Senior Notes - HEP | ' | -300,973 |
Proceeds from common unit offerings | ' | 73,444 |
Principal tender on senior notes - HEP | 0 | ' |
Purchase of treasury stock | -133,150 | -184,947 |
Contribution from General Partner | ' | 1,499 |
Dividends | -485,766 | -485,411 |
Distributions to noncontrolling interest | 0 | 0 |
Excess tax benefit from equity based compensation | 4,482 | 2,739 |
Purchase of units for restricted grants - HEP | 0 | ' |
Deferred financing costs and other | 3,995 | 912 |
Net advances from subsidiaries | 0 | 0 |
Net cash provided by (used for) financing activities | -618,429 | -895,735 |
Increase (decrease) for the period | -79,392 | -469,198 |
Beginning of period | 933,751 | 1,752,462 |
End of period | 854,359 | 1,283,264 |
Non-Guarantor Non-Restricted Subsidiaries (HEP Segment) [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Cash flows from operating activities | 140,154 | 124,922 |
Additions to properties, plants and equipment | 0 | -31,099 |
Payments to Acquire Businesses, Net of Cash Acquired | ' | 0 |
Proceeds from sale of assets | ' | -2,481 |
Investment in Sabine Biofuels | 0 | 0 |
Net repayment from (advances to) Sabine Biofuels | 0 | ' |
Net repayment from (advances to) Sabine Biofuels | ' | 0 |
Purchases of marketable securities | 0 | 0 |
Sales and maturities of marketable securities | 0 | 0 |
Net Advances to Parent | 0 | 0 |
Net cash used for investing activities | -61,657 | -28,618 |
Net repayments under credit agreement b HEP | ' | 56,000 |
Net borrowings under credit agreement b HEP | -192,000 | ' |
Redemption of Senior Notes - HEP | ' | 0 |
Proceeds from common unit offerings | ' | 73,444 |
Principal tender on senior notes - HEP | -156,188 | ' |
Purchase of treasury stock | 0 | 0 |
Contribution from General Partner | ' | 1,499 |
Dividends | 0 | 0 |
Distributions to noncontrolling interest | -117,930 | -105,641 |
Excess tax benefit from equity based compensation | 0 | 0 |
Purchase of units for restricted grants - HEP | -1,064 | -3,379 |
Deferred financing costs and other | ' | -244 |
Net advances from subsidiaries | 0 | 0 |
Net cash provided by (used for) financing activities | -83,182 | -90,321 |
Increase (decrease) for the period | -4,685 | 5,983 |
Beginning of period | 6,352 | 5,237 |
End of period | 1,667 | 11,220 |
Eliminations [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Cash flows from operating activities | -59,457 | -52,806 |
Additions to properties, plants and equipment | 0 | 0 |
Proceeds from sale of assets | ' | 0 |
Investment in Sabine Biofuels | 0 | 0 |
Net repayment from (advances to) Sabine Biofuels | 0 | ' |
Net repayment from (advances to) Sabine Biofuels | ' | 0 |
Purchases of marketable securities | 0 | 0 |
Sales and maturities of marketable securities | 0 | 0 |
Net Advances to Parent | 0 | 0 |
Net cash used for investing activities | 0 | 0 |
Redemption of Senior Notes - HEP | ' | 0 |
Principal tender on senior notes - HEP | 0 | ' |
Purchase of treasury stock | 0 | 0 |
Contribution from General Partner | ' | 0 |
Dividends | 0 | 0 |
Distributions to noncontrolling interest | 59,457 | 52,806 |
Excess tax benefit from equity based compensation | 0 | 0 |
Purchase of units for restricted grants - HEP | 0 | 0 |
Deferred financing costs and other | 0 | 0 |
Net advances from subsidiaries | 0 | 0 |
Net cash provided by (used for) financing activities | 59,457 | 52,806 |
Increase (decrease) for the period | 0 | 0 |
Beginning of period | 0 | 0 |
End of period | 0 | 0 |
HEP [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Additions to properties, plants and equipment | -61,657 | -31,099 |
Payments to Acquire Businesses, Net of Cash Acquired | ' | 11,301 |
Proceeds from sale of assets | 0 | ' |
Proceeds from common unit offerings | ' | 73,444 |
Principal tender on senior notes - HEP | -156,188 | 0 |
Distributions to noncontrolling interest | -58,473 | -52,835 |
Purchase of units for restricted grants - HEP | -1,064 | -3,379 |
Deferred financing costs and other | 0 | ' |
Beginning of period | 6,352 | ' |
End of period | 1,667 | ' |
HEP [Member] | Parent Company [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Additions to properties, plants and equipment | 0 | 0 |
Payments to Acquire Businesses, Net of Cash Acquired | ' | 0 |
Proceeds from sale of assets | 0 | ' |
Net repayments under credit agreement b HEP | ' | 0 |
Proceeds from common unit offerings | ' | 73,444 |
Purchase of units for restricted grants - HEP | ' | 0 |
HEP [Member] | Guarantor Restricted Subsidiaries [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Additions to properties, plants and equipment | 0 | 0 |
Payments to Acquire Businesses, Net of Cash Acquired | ' | 11,301 |
Proceeds from sale of assets | -14,711 | ' |
Net repayments under credit agreement b HEP | ' | 0 |
Purchase of units for restricted grants - HEP | ' | 0 |
HEP [Member] | Non Guarantor Restricted Subsidiaries [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Additions to properties, plants and equipment | 0 | 0 |
Payments to Acquire Businesses, Net of Cash Acquired | ' | 0 |
Proceeds from sale of assets | 0 | ' |
Net repayments under credit agreement b HEP | ' | 0 |
Purchase of units for restricted grants - HEP | ' | 0 |
HEP [Member] | Eliminations [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Additions to properties, plants and equipment | 0 | ' |
HEP [Member] | Holly Frontier Corp. Before Consolidation Of HEP [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Additions to properties, plants and equipment | 0 | 0 |
Payments to Acquire Businesses, Net of Cash Acquired | ' | 11,301 |
Proceeds from sale of assets | -14,711 | ' |
Net repayments under credit agreement b HEP | ' | 0 |
Purchase of units for restricted grants - HEP | ' | 0 |
HEP [Member] | Eliminations [Member] | ' | ' |
Condensed Financial Statements, Captions [Line Items] | ' | ' |
Additions to properties, plants and equipment | 0 | 0 |
Payments to Acquire Businesses, Net of Cash Acquired | ' | 0 |
Proceeds from sale of assets | 0 | ' |
Net repayments under credit agreement b HEP | ' | 0 |
Net borrowings under credit agreement b HEP | 0 | ' |
Proceeds from common unit offerings | ' | $0 |